Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model CAMBRIDGE, Mass. and TAIPEI, July 15, 2026 /PRNewswire/ -- Insilico...
At the forefront of AI and digital innovation in higher education
Honoured with two major industry awards recognising sustained excellence in AI innovation and digital transformation, reinforcing its commitment to future-ready education. SINGAPORE, May 22, 2026 /PRNewswire/ -- Kaplan Higher Education Academy...
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will...
Blaize Announces Pricing of $35 Million Public Offering of Common Stock
EL DORADO HILLS, Calif., May 6, 2026 /PRNewswire/ -- Blaize Holdings, Inc. (Nasdaq: BZAI, Nasdaq: BZAIW) ("Blaize," the "Company," "we," "our," or "us"), a leader in programmable, energy-efficient AI computing, announced today the pricing of its...
Blaize and Nokia Advance Collaboration with Joint AI Solution Showcase at GITEX Asia
EL DORADO HILLS, Calif. and SINGAPORE, March 31, 2026 /PRNewswire/ -- Blaize Holdings, Inc. (Nasdaq: BZAI, Nasdaq: BZAIW) ("Blaize"), a global leader in programmable, energy efficient AI computing, today announced the next phase of its collaboration...
NYSE Content Update: Snowflake to Unveil AI Platform to Get Work Done Faster
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, March 18, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE...
AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an...
Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange
SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks...
Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO
HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming...
AI platform assists workers 24/7
BEIJING, Dec. 19, 2025 /PRNewswire/ -- A news report from China Daily: LI MIN / CHIINA DAILY The All-China Federation of Trade Unions has revealed an artificial intelligence-powered platform that acts as a round-the-clock digital assistant, offering...